Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mian Xi

Showing results (61-70 of 108) with videos related to

Pageof 11
Sort By:
Cancers|December 19, 2018
Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus SorafenibLujun Shen, Mian Xi, Lei Zhao, et al.
Annals of Medicine|October 22, 2025
Pan-immune-inflammation value predicts survival of patients with oesophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: a pooled analysis of two phase II trialsXingyuan Cheng, Kongjia Luo, Yilu Gao, et al.
Annals of Surgical Oncology|September 9, 2018
Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance StrategiesSha Zhou, Shiliang Liu, Li Zhang, et al.
Annals of Surgical Oncology|September 20, 2022
Clinical and Dosimetric Predictors for Postoperative Cardiopulmonary Complications in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy and SurgeryZhaohui Liang, Kongjia Luo, Yuting Wang, et al.
Annals of Surgical Oncology|July 29, 2015
Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?Shi-Liang Liu, Mian Xi, Hong Yang, et al.
Eclinicalmedicine|September 16, 2024
Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trialRuixi Wang, Yihong Ling, Baoqing Chen, et al.
Journal of Oncology|June 23, 2020
Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort StudyYizhen Fu, Mian Xi, Yangxun Pan, et al.
Plos One|June 6, 2013
Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosisMian Xi, Li Zhang, Lei Zhao, et al.
International Journal of Surgery (London, England)|August 2, 2024
Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort studyYizhen Fu, Zhoutian Yang, Shiliang Liu, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 6, 2012
The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatinLei Zhao, Qiao-Qiao Li, Rui Zhang, et al.
Pageof 11

Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
Cancers|December 19, 2018
Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus SorafenibLujun Shen, Mian Xi, Lei Zhao, et al.
Annals of Medicine|October 22, 2025
Pan-immune-inflammation value predicts survival of patients with oesophageal squamous cell carcinoma receiving immunotherapy and chemoradiotherapy: a pooled analysis of two phase II trialsXingyuan Cheng, Kongjia Luo, Yilu Gao, et al.
Annals of Surgical Oncology|September 9, 2018
Recurrence Risk Based on Pathologic Stage After Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Implications for Risk-Based Postoperative Surveillance StrategiesSha Zhou, Shiliang Liu, Li Zhang, et al.
Annals of Surgical Oncology|September 20, 2022
Clinical and Dosimetric Predictors for Postoperative Cardiopulmonary Complications in Esophageal Squamous Cell Carcinoma Patients Receiving Neoadjuvant Chemoradiotherapy and SurgeryZhaohui Liang, Kongjia Luo, Yuting Wang, et al.
Annals of Surgical Oncology|July 29, 2015
Is There a Correlation Between Clinical Complete Response and Pathological Complete Response After Neoadjuvant Chemoradiotherapy for Esophageal Squamous Cell Cancer?Shi-Liang Liu, Mian Xi, Hong Yang, et al.
Eclinicalmedicine|September 16, 2024
Long-term survival and post-hoc analysis of toripalimab plus definitive chemoradiotherapy for oesophageal squamous cell carcinoma: insights from the EC-CRT-001 phase II trialRuixi Wang, Yihong Ling, Baoqing Chen, et al.
Journal of Oncology|June 23, 2020
Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Cohort StudyYizhen Fu, Mian Xi, Yangxun Pan, et al.
Plos One|June 6, 2013
Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosisMian Xi, Li Zhang, Lei Zhao, et al.
International Journal of Surgery (London, England)|August 2, 2024
Comparison of resection, ablation, and stereotactic body radiation therapy in treating solitary hepatocellular carcinoma ≤5 cm: a retrospective, multicenter, cohort studyYizhen Fu, Zhoutian Yang, Shiliang Liu, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|March 6, 2012
The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatinLei Zhao, Qiao-Qiao Li, Rui Zhang, et al.
Pageof 11